Targeted therapies for lung cancer

Clinical experience and novel agents

Jill E. Larsen, Tina Cascone, David E. Gerber, John V. Heymach, John D. Minna

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Although lung cancer remains the leading cancer killer in the United States, recently a number of developments indicate future clinical benefit. These include evidence that computed tomography-based screening decreases lung cancer mortality, the use of stereotactic radiation for early-stage tumors, the development of molecular methods to predict chemotherapy sensitivity, and genome-wide expression and mutation analysis data that have uncovered oncogene "addictions" as important therapeutic targets. Perhaps the most significant advance in the treatment of this challenging disease is the introduction of molecularly targeted therapies, a term that currently includes monoclonal antibodies and small-molecule tyrosine kinase inhibitors. The development of effective targeted therapeutics requires knowledge of the genes and pathways involved and how they relate to the biologic behavior of lung cancer. Drugs targeting the epidermal growth factor receptor, anaplastic lymphoma kinase, and vascular endothelial growth factor are now U.S. Food and Drug Administration approved for the treatment of advanced non-small cell lung cancer. These agents are generally better tolerated than conventional chemotherapy and show dramatic efficacy when their use is coupled with a clear understanding of clinical data, mechanism, patient selection, drug interactions, and toxicities. Integrating genome-wide tumor analysis with drug- and targeted agent-responsive phenotypes will provide a wealth of new possibilities for lung cancer-targeted therapeutics. Ongoing research efforts in these areas as well as a discussion of emerging targeted agents being evaluated in clinical trials are the subjects of this review.

Original languageEnglish (US)
Pages (from-to)512-527
Number of pages16
JournalCancer Journal
Volume17
Issue number6
DOIs
StatePublished - Nov 2011

Fingerprint

Lung Neoplasms
Therapeutics
Genome
Drug Therapy
Neoplasms
United States Food and Drug Administration
Drug Delivery Systems
Drug-Related Side Effects and Adverse Reactions
Drug Interactions
Oncogenes
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Patient Selection
Vascular Endothelial Growth Factor A
Monoclonal Antibodies
Tomography
Clinical Trials
Radiation
Phenotype

Keywords

  • ALK
  • EGFR
  • genome-wide tumor analysis
  • Lung cancer
  • monoclonal antibody
  • targeted therapies
  • tyrosine kinase inhibitor
  • VEGF

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Targeted therapies for lung cancer : Clinical experience and novel agents. / Larsen, Jill E.; Cascone, Tina; Gerber, David E.; Heymach, John V.; Minna, John D.

In: Cancer Journal, Vol. 17, No. 6, 11.2011, p. 512-527.

Research output: Contribution to journalArticle

Larsen, Jill E. ; Cascone, Tina ; Gerber, David E. ; Heymach, John V. ; Minna, John D. / Targeted therapies for lung cancer : Clinical experience and novel agents. In: Cancer Journal. 2011 ; Vol. 17, No. 6. pp. 512-527.
@article{79f8c468c057434da0be95f94e8f1865,
title = "Targeted therapies for lung cancer: Clinical experience and novel agents",
abstract = "Although lung cancer remains the leading cancer killer in the United States, recently a number of developments indicate future clinical benefit. These include evidence that computed tomography-based screening decreases lung cancer mortality, the use of stereotactic radiation for early-stage tumors, the development of molecular methods to predict chemotherapy sensitivity, and genome-wide expression and mutation analysis data that have uncovered oncogene {"}addictions{"} as important therapeutic targets. Perhaps the most significant advance in the treatment of this challenging disease is the introduction of molecularly targeted therapies, a term that currently includes monoclonal antibodies and small-molecule tyrosine kinase inhibitors. The development of effective targeted therapeutics requires knowledge of the genes and pathways involved and how they relate to the biologic behavior of lung cancer. Drugs targeting the epidermal growth factor receptor, anaplastic lymphoma kinase, and vascular endothelial growth factor are now U.S. Food and Drug Administration approved for the treatment of advanced non-small cell lung cancer. These agents are generally better tolerated than conventional chemotherapy and show dramatic efficacy when their use is coupled with a clear understanding of clinical data, mechanism, patient selection, drug interactions, and toxicities. Integrating genome-wide tumor analysis with drug- and targeted agent-responsive phenotypes will provide a wealth of new possibilities for lung cancer-targeted therapeutics. Ongoing research efforts in these areas as well as a discussion of emerging targeted agents being evaluated in clinical trials are the subjects of this review.",
keywords = "ALK, EGFR, genome-wide tumor analysis, Lung cancer, monoclonal antibody, targeted therapies, tyrosine kinase inhibitor, VEGF",
author = "Larsen, {Jill E.} and Tina Cascone and Gerber, {David E.} and Heymach, {John V.} and Minna, {John D.}",
year = "2011",
month = "11",
doi = "10.1097/PPO.0b013e31823e701a",
language = "English (US)",
volume = "17",
pages = "512--527",
journal = "Cancer Journal (United States)",
issn = "1528-9117",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Targeted therapies for lung cancer

T2 - Clinical experience and novel agents

AU - Larsen, Jill E.

AU - Cascone, Tina

AU - Gerber, David E.

AU - Heymach, John V.

AU - Minna, John D.

PY - 2011/11

Y1 - 2011/11

N2 - Although lung cancer remains the leading cancer killer in the United States, recently a number of developments indicate future clinical benefit. These include evidence that computed tomography-based screening decreases lung cancer mortality, the use of stereotactic radiation for early-stage tumors, the development of molecular methods to predict chemotherapy sensitivity, and genome-wide expression and mutation analysis data that have uncovered oncogene "addictions" as important therapeutic targets. Perhaps the most significant advance in the treatment of this challenging disease is the introduction of molecularly targeted therapies, a term that currently includes monoclonal antibodies and small-molecule tyrosine kinase inhibitors. The development of effective targeted therapeutics requires knowledge of the genes and pathways involved and how they relate to the biologic behavior of lung cancer. Drugs targeting the epidermal growth factor receptor, anaplastic lymphoma kinase, and vascular endothelial growth factor are now U.S. Food and Drug Administration approved for the treatment of advanced non-small cell lung cancer. These agents are generally better tolerated than conventional chemotherapy and show dramatic efficacy when their use is coupled with a clear understanding of clinical data, mechanism, patient selection, drug interactions, and toxicities. Integrating genome-wide tumor analysis with drug- and targeted agent-responsive phenotypes will provide a wealth of new possibilities for lung cancer-targeted therapeutics. Ongoing research efforts in these areas as well as a discussion of emerging targeted agents being evaluated in clinical trials are the subjects of this review.

AB - Although lung cancer remains the leading cancer killer in the United States, recently a number of developments indicate future clinical benefit. These include evidence that computed tomography-based screening decreases lung cancer mortality, the use of stereotactic radiation for early-stage tumors, the development of molecular methods to predict chemotherapy sensitivity, and genome-wide expression and mutation analysis data that have uncovered oncogene "addictions" as important therapeutic targets. Perhaps the most significant advance in the treatment of this challenging disease is the introduction of molecularly targeted therapies, a term that currently includes monoclonal antibodies and small-molecule tyrosine kinase inhibitors. The development of effective targeted therapeutics requires knowledge of the genes and pathways involved and how they relate to the biologic behavior of lung cancer. Drugs targeting the epidermal growth factor receptor, anaplastic lymphoma kinase, and vascular endothelial growth factor are now U.S. Food and Drug Administration approved for the treatment of advanced non-small cell lung cancer. These agents are generally better tolerated than conventional chemotherapy and show dramatic efficacy when their use is coupled with a clear understanding of clinical data, mechanism, patient selection, drug interactions, and toxicities. Integrating genome-wide tumor analysis with drug- and targeted agent-responsive phenotypes will provide a wealth of new possibilities for lung cancer-targeted therapeutics. Ongoing research efforts in these areas as well as a discussion of emerging targeted agents being evaluated in clinical trials are the subjects of this review.

KW - ALK

KW - EGFR

KW - genome-wide tumor analysis

KW - Lung cancer

KW - monoclonal antibody

KW - targeted therapies

KW - tyrosine kinase inhibitor

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=83755188025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83755188025&partnerID=8YFLogxK

U2 - 10.1097/PPO.0b013e31823e701a

DO - 10.1097/PPO.0b013e31823e701a

M3 - Article

VL - 17

SP - 512

EP - 527

JO - Cancer Journal (United States)

JF - Cancer Journal (United States)

SN - 1528-9117

IS - 6

ER -